Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients (pts) with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 12, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

AI-driven single blood cell classification
(Helmholtz Zentrum M ü nchen - German Research Center for Environmental Health) For the first time, researchers from Helmholtz Zentrum M ü nchen and the University Hospital of LMU Munich show that deep learning algorithms perform similar to human experts when classifying blood samples from patients suffering from acute myeloid leukemia (AML). Their proof of concept study paves the way for an automated, standardized and on-hand sample analysis in the near future. The paper was published in Nature Machine Intelligence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 12, 2019 Category: Cancer & Oncology Source Type: news

Gilteritinib Improves Survival in Patients with Relapsed/Refractory FLT3+ AML
Treatment with gilteritinib improved survival and increased remission rates, compared with salvage chemotherapy, among patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Gilteritinib Superior in Relapsed, Refractory FLT3-Mutated AML
THURSDAY, Oct. 31, 2019 -- For relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3), treatment with a selective FLT3 inhibitor, gilteritinib, results in significantly longer survival and a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2019 Category: Pharmaceuticals Source Type: news

SY-1425 Combination Shows Promise in Acute Myeloid Leukemia Subgroup
Treatment with SY-1425 in combination with azacitidine induced a 62% complete response rate with incomplete blood count recovery rate among unfit patients with RARA-positive AML. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat(R) CDx FLT3 Mutation Assay
SAN DIEGO, Oct. 30, 2019 -- (Healthcare Sales & Marketing Network) -- Invivoscribe, Inc. announced today that the European Commission (EC) has approved the Astellas drug XOSPATA™ (gilteritinib) as a monotherapy for the treatment of adult patients with rel... Diagnostics, Oncology, Regulatory Invivoscribe, Astellas, XOSPATA, gilteritinib, LeukoStrat CDx FLT3 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 30, 2019 Category: Pharmaceuticals Source Type: news

European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Approval follows accelerated assessment, orphan designation by European Medicines Agency TOKYO, Oct. 25, 2019 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") ... Biopharmaceuticals, Oncology, Regulatory Astellas Pharma, XOSPATA, gilteritinib, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2019 Category: Pharmaceuticals Source Type: news

Outcomes Associated with Antimicrobial Use during High Dose Cytarabine Consolidation in Acute Myeloid Leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 8, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Seifem 2016 Study: Incidence of Probable and Proven Invasive Aspergillosis in Patients with Acute Myeloid Leukemia during Consolidation Therapy
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Invasive Aspergillosis (IA) in Acute Myeloid Leukemia (AML): When Is Prophylaxis Appropriate?
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Therapeutic Drug Monitoring of Posaconazole in Adult Acute Myeloid Leukemia (Aml) Patients Receiving Posaconazole Prophylaxis during Induction: Experience from a Center with High Invasive Fungal Infection (IFI)Burden
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 4, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Novel Risk Factors for Predicting the Development of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Undergoing Induction and Re-Induction Chemotherapy
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 4, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 4, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news